Phase 2 SLL Clinical Trials
12 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–12 of 12 trials
Recruiting
Phase 2
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
Nurix Therapeutics, Inc.100 enrolled20 locationsNCT07221500
Recruiting
Phase 1Phase 2
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
T-lymphoblastic LymphomaRelapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL+3 more
Beijing Biotech96 enrolled1 locationNCT07523555
Recruiting
Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Leukemia (SLL)
Memorial Sloan Kettering Cancer Center230 enrolled8 locationsNCT03824483
Recruiting
Phase 2
Study of Epcoritamab as a Consolidation Therapy in CLL/SLL
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaCLL+4 more
Zulfa Omer22 enrolled1 locationNCT07108998
Recruiting
Phase 2
REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)
CLL/SLL
Stichting Hemato-Oncologie voor Volwassenen Nederland60 enrolled18 locationsNCT04523428
Recruiting
Phase 2
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
AbbVie110 enrolled31 locationsNCT02966756
Recruiting
Phase 2
Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
Dana-Farber Cancer Institute45 enrolled4 locationsNCT05168930
Recruiting
Phase 2
Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy
Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)
The First Affiliated Hospital with Nanjing Medical University79 enrolled1 locationNCT06958705
Recruiting
Phase 2
Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).
Chronic Lymphocytic LeukemiaSmall Lymphocytic Leukemia (SLL)
M.D. Anderson Cancer Center40 enrolled1 locationNCT06967610
Recruiting
Phase 2
Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLL
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma (SLL)
Massachusetts General Hospital40 enrolled2 locationsNCT06849713
Recruiting
Phase 2
LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaCLL/SLL+1 more
Zulfa Omer34 enrolled1 locationNCT06978088
Recruiting
Phase 1Phase 2
Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL
CLL/SLL
Stichting Hemato-Oncologie voor Volwassenen Nederland112 enrolled24 locationsNCT05791409